Immunotherapy using human melanoma epitopes recognized by T cells

Yutaka Kawakami

Research output: Contribution to journalArticle

Abstract

Tumor reactive T cells can be induced from peripheral blood or tumor infiltrating lymphocytes of patients with melanoma. Based on the analysis of the previous immunotherapies, T cells appeared to be involved in vivo tumor regression. Genes encoding human melanoma antigens and their epitope peptides recognized by T cells, have been identified using cDNA expression cloning techniques. Mechanisms for generation of T cell epitopes on growing melanoma cells have been identified. A variety of Phase I clinical studies using MART- 1 and gp100 antigens are being performed in the Surgery Branch, National Cancer Institute, NIH, and some patients have responded to these immunotherapy protocols.

Original languageEnglish
Pages (from-to)542-548
Number of pages7
JournalBiotherapy
Volume12
Issue number5
Publication statusPublished - 1998

Fingerprint

T-Lymphocyte Epitopes
Immunotherapy
Melanoma
T-Lymphocytes
MART-1 Antigen
Melanoma-Specific Antigens
Peptide T
Tumor-Infiltrating Lymphocytes
National Cancer Institute (U.S.)
Organism Cloning
Epitopes
Neoplasms
Complementary DNA
Genes

Keywords

  • Dendritic cells
  • Gp100
  • MART-1
  • Melanoma
  • T cells
  • Tumor antigens

ASJC Scopus subject areas

  • Cancer Research
  • Immunology and Allergy

Cite this

Immunotherapy using human melanoma epitopes recognized by T cells. / Kawakami, Yutaka.

In: Biotherapy, Vol. 12, No. 5, 1998, p. 542-548.

Research output: Contribution to journalArticle

Kawakami, Y 1998, 'Immunotherapy using human melanoma epitopes recognized by T cells', Biotherapy, vol. 12, no. 5, pp. 542-548.
Kawakami, Yutaka. / Immunotherapy using human melanoma epitopes recognized by T cells. In: Biotherapy. 1998 ; Vol. 12, No. 5. pp. 542-548.
@article{cc40735ab4b240eda1cf25d223be1774,
title = "Immunotherapy using human melanoma epitopes recognized by T cells",
abstract = "Tumor reactive T cells can be induced from peripheral blood or tumor infiltrating lymphocytes of patients with melanoma. Based on the analysis of the previous immunotherapies, T cells appeared to be involved in vivo tumor regression. Genes encoding human melanoma antigens and their epitope peptides recognized by T cells, have been identified using cDNA expression cloning techniques. Mechanisms for generation of T cell epitopes on growing melanoma cells have been identified. A variety of Phase I clinical studies using MART- 1 and gp100 antigens are being performed in the Surgery Branch, National Cancer Institute, NIH, and some patients have responded to these immunotherapy protocols.",
keywords = "Dendritic cells, Gp100, MART-1, Melanoma, T cells, Tumor antigens",
author = "Yutaka Kawakami",
year = "1998",
language = "English",
volume = "12",
pages = "542--548",
journal = "Biotherapy",
issn = "0914-2223",
publisher = "Japanese Society for Cancer Chemotherapy",
number = "5",

}

TY - JOUR

T1 - Immunotherapy using human melanoma epitopes recognized by T cells

AU - Kawakami, Yutaka

PY - 1998

Y1 - 1998

N2 - Tumor reactive T cells can be induced from peripheral blood or tumor infiltrating lymphocytes of patients with melanoma. Based on the analysis of the previous immunotherapies, T cells appeared to be involved in vivo tumor regression. Genes encoding human melanoma antigens and their epitope peptides recognized by T cells, have been identified using cDNA expression cloning techniques. Mechanisms for generation of T cell epitopes on growing melanoma cells have been identified. A variety of Phase I clinical studies using MART- 1 and gp100 antigens are being performed in the Surgery Branch, National Cancer Institute, NIH, and some patients have responded to these immunotherapy protocols.

AB - Tumor reactive T cells can be induced from peripheral blood or tumor infiltrating lymphocytes of patients with melanoma. Based on the analysis of the previous immunotherapies, T cells appeared to be involved in vivo tumor regression. Genes encoding human melanoma antigens and their epitope peptides recognized by T cells, have been identified using cDNA expression cloning techniques. Mechanisms for generation of T cell epitopes on growing melanoma cells have been identified. A variety of Phase I clinical studies using MART- 1 and gp100 antigens are being performed in the Surgery Branch, National Cancer Institute, NIH, and some patients have responded to these immunotherapy protocols.

KW - Dendritic cells

KW - Gp100

KW - MART-1

KW - Melanoma

KW - T cells

KW - Tumor antigens

UR - http://www.scopus.com/inward/record.url?scp=0031807012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031807012&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0031807012

VL - 12

SP - 542

EP - 548

JO - Biotherapy

JF - Biotherapy

SN - 0914-2223

IS - 5

ER -